Search

Deals with the concerns raised by medical professionals about the British National Health Service White Paper in February 2006. Statement issued by Richard Q. Lewis of King's Fund in London, England; Barrier to the proposed improvements in accessibility to healthcare services; Suggestion of Anthony Harrison of King's Fund.

Universal electronic prescriptions will save the UK NHS £300 million by 2021, according to a media release from NHS Digital. Patients without a nominated pharmacy will still receive a paper copy, which has a bar code that can be scanned by the pharmacist to download the electronic prescription from the NHS database. [Extracted from the article]

This article discusses a briefing paper on the incremental cost-effectiveness ratio (ICER) threshold of the NICE written by Christopher McCabe from the University of Leeds in England and colleagues. The paper reviews what the ICER threshold represents, what the appropriate level is and what other factors the NICE should consider. Moreover, the paper critically assesses utilization of the threshold by the NICE to inform its guidance.

The article focuses on a briefing paper written by Christopher McCabe and colleagues for the British National Institute for Clinical Excellence (NICE) published in the January 2008 issue of "PharmacoEconomics." The paper examines the incremental cost-effectiveness ratio (ICER) of NICE, its appropriate level and its utilisation by NICE. An explicit single threshold is recommended instead of the existing range, which is between £20,000 and £30,000. A lower threshold is suggested for interventions with a large budgetary impact.

This section offers news briefs on the pharmaceutical industry. It presents highlights from the September 2011 issue of Medsafe New Zealand's "Presciber Update." Batches of busulfan and bortezomib will be recalled in Great Britain due to a theoretical risk of contamination, according to an alert from the Medicines and Healthcare products Regulatory Agency (MHRA). The Australian Therapeutic Goods Administration (TGA) will develop a consultation paper on the labelling and packaging of medicines.

Pharmaswiss Ceska republika (Bausch & Lomb UK) is recalling all unexpired batches of epinephrine (Emerade) 500µg autoinjector pens due a product component fault, says the UK's MHRA. This recall of Emerade 500µg autoinjector pens follows recent recalls of Emerade 150µg autoinjector pens (in March this year) and Emerade 300µg autoinjector pens (in April this year). [Extracted from the article]

UK patients who carry epinephrine (adrenaline) 300µg auto-injector pens (Emerade) [1] should contact their prescriber to seek a replacement product, advises the UK's MHRA. Patients informed to exchange Emerade 300 micrograms adrenaline pens for replacement pens of a different brand. [Extracted from the article]

The article reports on a survey commissioned by the British Medical Association (BMA) regarding the reforms outlined in the British government's White Paper, "Equity and Excellence: Liberating the National Health Service (NHS)," where overall response expressed skepticism on the effectivity of the proposed reforms due to increased competition within the NHS, fragmentation of services and decreased quality of care.

The article reports on the decision of periodical "PharmacoEconomics" to dedicate its September 2008 issue to the fourth hurdle set by the British National Institute for Clinical Excellence (NICE) requiring pharmaceutical companies to demonstrate the cost effectiveness of their products. The issue addressed the health technology assessment and the cost-effectiveness rating and attaining National Health Service (NHS) reimbursement. It also includes the original briefing papers commissioned by NICE to inform companies of the requirements.

The article focuses on the recommended medical treatments by the British National Institute of Clinical Excellence (NICE) based on its consultation papers published on May 30 and June 4, 2007. NICE has recommended multiple myeloma patients with a full or partial response to bortezomib to continue such treatment. It also approved the use of varenicline as an optional treatment for adults who wish to quit smoking.